Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Renard, M
Right arrow Articles by Bernard, R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Renard, M
Right arrow Articles by Bernard, R

Chest, Vol 93, 1159-1164, Copyright © 1988 by American College of Chest Physicians

ARTICLES

Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short- term and one-month effects of a new inotropic vasodilating agent

M Renard, M Walter, I Liebens, A Dresse and R Bernard
Saint Pierre University Hospital, Brussels, Belgium.

We studied the effects of oral administration of pimobendane on hemodynamics, blood gas levels, the renin-angiotensin system, and plasma catecholamines in 11 patients who were affected by severe chronic congestive heart failure. Following the administration of 5 mg, the cardiac index increased from 2.0 +/- 0.2 to 2.5 +/- 0.2 L/min/m2 (p less than 0.01), and the pulmonary wedge pressure decreased from 28 +/- 3 to 17 +/- 4 mm Hg (p less than 0.01). The maximal changes were noted five hours after intake of the drug. In spite of a significant decrease in arterial oxygen pressure (PaO2) (from 81 +/- 4 to 67 +/- 5 mm Hg; p less than 0.05), a significant increase in the oxygen delivery index was seen (from 322 +/- 32 to 436 +/- 38 ml/min/m2; p less than 0.01). The patients who were submitted to long-term treatment (5 mg twice daily) and who were reassessed after at least one month exhibited an improved cardiac index from 1.9 +/- 0.2 to 2.5 +/- 0.1 L/min/m2 (p less than 0.01), as well as a decreased pulmonary wedge pressure from 26 +/- 2 to 14 +/- 4 mm Hg (p less than 0.01). The norepinephrine levels were significantly reduced after one month (from 1,496 +/- 185 to 678 +/- 95 pg/ml; p less than 0.01), whereas the plasma renin activity was not. One patient died suddenly during the one-month follow-up period. With the exception of one case, which was also treated with heparin, a transient cutaneous rash and a drop in the level of blood platelets were observed, pimobendane was well tolerated. This new inotropic and vasodilating drug thus seems to have promise for the treatment of chronic congestive heart failure.


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
K.-M. Chu, O. Y.-P. Hu, and S.-M. Shieh
Cardiovascular Effect and Simultaneous Pharmacokinetic and Pharmacodynamic Modeling of Pimobendan in Healthy Normal Subjects
Drug Metab. Dispos., June 1, 1999; 27(6): 701 - 709.
[Abstract] [Full Text]

Home page
 J Am Coll CardiolHome page
A. Iwasaki, A. Matsumori, T. Yamada, T. Shioi, W. Wang, K. Ono, R. Nishio, M. Okada, and S. Sasayama
Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis
J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1400 - 1407.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American College of Chest Physicians.